Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Mol Carcinog. 2011 Jan 25;50(9):655–667. doi: 10.1002/mc.20738

Figure 1.

Figure 1

CDODA-Me and CF3DODA-Me decrease thyroid cancer cell survival. ARO (A), DRO (B), K-18 (C), and HTh-74 (D) were treated with CDODA-Me or CF3DODA-Me for 24 or 48 hr, and cells were counted as described in the Materials and Methods. Results are expressed as means ± SE for three replicate determinations for each treatment group. Significantly (p < 0.05) decreased cell survival compared to DMSO (solvent) control (set at 100%) is indicated by an asterisk.